High-throughput oncogene mutation profiling in human cancer

@article{Thomas2007HighthroughputOM,
  title={High-throughput oncogene mutation profiling in human cancer},
  author={Roman K. Thomas and Alissa C. Baker and Ralph M. Debiasi and Wendy Winckler and Thomas LaFramboise and William M. Lin and Meilin Wang and Whei Feng and Thomas Zander and Laura Macconaill and Jeffrey C. Lee and Richard Nicoletti and Charles Hatton and Mary Goyette and Luc Girard and Kuntal Majmudar and Liuda Ziaugra and Kwok-Kin Wong and S. Gabriel and Rameen Beroukhim and Michael Peyton and Jordi Barretina and Amit Dutt and Caroline M. Emery and Heidi Greulich and Kinjal K. Shah and Hidefumi Sasaki and Adi F. Gazdar and John D. Minna and Scott A. Armstrong and Ingo K. Mellinghoff and F. Stephen Hodi and Glenn Dranoff and Paul S. Mischel and Timothy F. Cloughesy and Stanley F. Nelson and Linda M. Liau and Kirsten D. Mertz and Mark A. Rubin and Holger Moch and Massimo Loda and William J. Catalona and Jonathan A. Fletcher and Sabina Signoretti and Frederic J Kaye and Kenneth C. Anderson and George D. Demetri and Reinhard Dummer and Stephan N Wagner and Meenhard Herlyn and William R. Sellers and Matthew L Meyerson and Levi A. Garraway},
  journal={Nature Genetics},
  year={2007},
  volume={39},
  pages={347-351}
}
Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions… Expand
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
TLDR
The implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting and demonstrates the clinical feasibility of high-throughput mutation profiling to query a large panel of “actionable” cancer gene mutations is reported. Expand
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
TLDR
It is suggested that RAS mutation is not a binary variable in tumors, and that the diversity in mutant alleles and variability in gene copy number may also contribute to the heterogeneity of clinical outcomes observed in cancer patients. Expand
A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
TLDR
A high-throughput mutation panel for the identification of frequently occurring and clinically relevant mutations in melanoma is developed and may rapidly and accurately identify potentially effective treatment strategies using novel or existing molecularly targeted drugs. Expand
PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations
TLDR
These findings suggest that PIK3CA mutations may be a relatively late event and may function primarily in a supporting/modifying role, and not as a primary driver of oncogenesis, and when other pro-oncogenic pathways are mutated along with Pik3CA, then, Piken3CA inhibition alone may not be effective and combination therapy may be warranted. Expand
Concordance and discordance in tumor genomic profiling.
  • L. Garraway
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
A genomic profiling study of frozen CRC specimens obtained from more than 600 patients identified known activating mutations in KRAS, NRAS, BRAF, and PIK3CA oncogenes, which are commonly mutated in CRC, and found the mutational concordance between matched pairs across the five cancer genes analyzed ranged from 89% to 95%. Expand
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
TLDR
An integrative study on the clinically annotated genomic data released by The Cancer Genome Atlas suggested the potential existence of epistatic interaction effects among the mutations in different cancer driver genes on clinical outcomes. Expand
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
TLDR
A highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding tissue, and tests for 120 previously described mutations in 13 cancer genes, establishes a platform for real‐time targeted genotyping that can be widely adopted. Expand
High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma
TLDR
Using high throughput mutation screening platform, it was identified that PIK3CA mutations were the most frequently observed target for gastric adenocarcinoma. Expand
Cancer driver mutations in protein kinase genes.
TLDR
Recent progress in the discovery and functional characterization of protein kinase cancer driver mutations is discussed and the implications for understanding tumorigenesis as well as the design of 'personalized' cancer therapeutics that target an individual's unique mutational profile are discussed. Expand
Mutational profiling of glioblastoma
A recent systematic sequence analysis of well-annotated human protein coding genes or consensus coding sequences led to the identification of 1149 genes displaying somatic mutations in breast andExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
TLDR
The sequence of well-annotated human protein-coding genes in two common tumor types is determined to define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology. Expand
Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
TLDR
By applying high-throughput genomic resequencing, a novel therapeutic target is identified, mutant EGFR, in lung cancer and its role in predicting response to targeted therapy is evaluated. Expand
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
TLDR
Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCi-60 cell lines for molecularly targeted screens. Expand
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
TLDR
How high-throughput screening methods, including gene-expression profiling and proteomics, and emerging methods for analyzing complex cellular networks can be used to identify the state of oncogene addiction, i.e. the 'Achilles' heel,' in specific cancers are discussed. Expand
Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML
TLDR
It was found that hypomethylation at all three loci examined was a common feature of Wilms tumour, however, there were no significant differences in the proportion demonstrating satellite hypometHylation between tumours that relapsed versus those that did not. Expand
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.
TLDR
This study transfected mutant c-kit cDNA into an interleukin 3-dependent Ba/F3 murine lymphoid cell line, and the magnitude of autophosphorylation of the mutant KIT was examined with or without stem cell factor, a ligand of KIT. Expand
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
TLDR
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website have been developed to store somatic mutation data in a single location and display the data and other information related to human cancer. Expand
Missense mutations of the BRAF gene in human lung adenocarcinoma.
TLDR
Analysis of BRAF sequence from 127 primary human lung adenocarcinomas revealed mutations in two tumor specimens, one in exon 11 (G465V), and a second inExon 15 (L596R), which belong to the same adenOCarcinoma subgroup as defined by clustering of gene expression data. Expand
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
TLDR
Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. Expand
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification.
Major efforts are underway to systematically define the somatic and germline genetic variations causally associated with disease. Genome-wide genetic analysis of actual clinical samples is, however,Expand
...
1
2
3
...